Systemic lupus erythematosus with hematological symptoms – a multifaceted disease: case reports and summary for clinical practice

Czech version

Authors: K. Bouchalova ¹; H. Flögelová ¹; P. Horák ²; M. Skácelová ²; D. Dvořák ¹; M. Schüller ³; D. Pospíšilová ¹
Authors‘ workplace: Dětská klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého, Olomouc ¹; III. interní klinika NRE, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého, Olomouc ²; Pediatrická klinika, Lékařská fakulta, Masarykova univerzita a Fakultní nemocnice Brno ³
Published in: Čes-slov Pediat 2021; 76 (6): 304-312.
Category: Original Papers

Overview

Systemic lupus erythematosus (SLE) is a severe highly heterogenous multisystemic inflammatory disease, characterized by a combination of clinical and immunological criteria.

The aim of a paper is to show variability of clinical and hematological findings, that could be first symptoms of developing SLE and might precede diagnosis by different time ranging from weeks to many years. These findings encompasses immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, and asymptomatic strong positivity of anticardiolipine antibodies, which lasted from one month to 7 years in our patients. We highlight an importance of early assessment of autoantibodies in patients with these hematologic diseases and need for a deep collaboration between hematologist and rheumatologist, which is a quarantee of early SLE diagnosis and therapy initiation.

Keywords:

arthritis – Systemic lupus erythematosus – Hemolytic anemia – therapy – diagnostics – 2019 EULAR/ACR classification criteria – SLICC classification criteria – antiphospholipid antibodies – immune thrombocytopenic purpura

Sources

1. Klein-Gitelman MS, Beresford MW. Systemic lupus erythematosus. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC. Textbook of Pediatric Rheumatology. 8th ed. Elsevier, 2021: 295–329.

2. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis 2017; 76 (10): 1637–1641.

3. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017; 76 (11): 1788–1796.

4. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017; 76 (12): 1965–1973.

5. Malcova H, Vargova V. Juvenilní systémový lupus erytematodes. In: Doležalová P, Dallos T. Dětská revmatologie v praxi. 1. vyd. Praha: Mladá fronta, 2019: 300–311.

6. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 2019; 71 (9): 1400–1412.

7. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

8. Laxer RM, Cellucci T, Rozenblyum E, et al. A Residents’s Guide to Pediatric Rheumatology. 4th rev ed. Toronto: The Hospital For Sick Children, 2019: 35–38.

9. Rood MJ, ten Cate R, van Suijlekom-Smit LWA, et al. Children – onset lupus erythematosus. Scand J Rheumatol 1999; 28: 222–226.

10. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736–745.

11. Henyšová V, Olejárová M, Moravcová R. Validizace screeningového dotazníku pro přítomnost neuropsychiatrických symptomů u pacientů se systémovým lupusem erythematodem v klinické praxi. Čes Revmatol 2016; 24 (4): 154–161.

12. Holers VM. Systemic lupus erytematosus. The complement system. In: Klippel J, Dieppe P (Eds). Rheumatology. 2nd ed. London: Mosby, 1998.

13. Silverman E. Systemic lupus erythematosus in children. In: Madison PJ, Isenberg DA, Woo P, Glass DN. Oxford Textbook of Rheumatology. 2nd ed. Oxford University Press, 1998.

14. Schett G, Firbas U, Fureder W, et al. Decreased resum erythropoietin and its relation to anti-erythropoietin antibodies in anemia of systemic upus erythematosus. Rheumatology 2001; 40: 424–431.

15. Doležalová P, Hoza J. Systémový lupus erythematodes. In: Havelka S, Hoza J a kol. Revmatologie období růstu. Praha: Maxdorf, 2004: 107–136.

16. Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am 2005; 52: 443–467.

17. Smith EMD, Yin P, Jorgensen AL, et al. Clinical predictors of active LN development in children – evidence from the UK JSLE Cohort Study. Lupus 2018; 27: 2020–2028.

18. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association – European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79: 713–723.

19. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: classification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018; 93: 789–796.

20. Turnier JL, Fall N, Thornton S, et al. Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Res Ther 2017; 19: 242.

21. Costa-Reis P, Russo PA, Zhang Z, et al. The role of microRNAs and human epidermal growth factor receptor 2 in proliferative lupus nephritis. Arthritis Rheumatol 2015; 67: 2415–2426.

22. Costa-Reis P, Maurer K, Schanberg LE, et al. HER2 as a urinary biomarker of lupus nephritis aktivity: results of a multicenter pediatric prospective study and an adult study. Pediatr Rheumatol 2018; 16 (Suppl 2): P266.